Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

A 68-year-old man having a descending colon cancer with multiple metastases of up to 9.5 cm in the right lobe of the liver(T3, N0, M1a)underwent laparoscopic colon resection for anemia control. Chemotherapy with mFOLFOX6 plus Bmab was administered postoperatively. Because this treatment had little effect, FOLFIRI plus Pmab was initiated 3 months later. A significant reduction in the tumor size was observed. Therefore, we performed laparotomy. However, the liver metastasis had invaded the inferior vena cava, which was not resectable. After the second surgery, we introduced the 5-FU hepatic arterial injection port ia plus Pmab iv, which was effective for 8 months. We then restarted chemotherapy with FOLFIRI plus Pmab. However, the tumor became more enlarged; therefore, we changed the chemotherapy regimen to SOX plus Bmab. Partial reduction in the tumor size was observed again, and the effects lasted for a while. The patient continued visiting the outpatient clinic with almost no symptoms for more than 1 year. He died of the primary cancer 3 years and 8 months after the first visit. We report a case of liver metastasis of colon cancer that could have been controlled successfully by repeatedly using the same pharmacotherapy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

colon cancer
12
multiple metastases
8
folfiri pmab
8
reduction tumor
8
tumor size
8
size observed
8
liver metastasis
8
case colon
4
cancer
4
cancer synchronous
4

Similar Publications

Background: To evaluate predictors of outcomes in colorectal liver metastases (CLM) patients undergoing 90Y radioembolization (TARE), focusing on the impact of tumor absorbed dose.

Materials And Methods: Patients' characteristics and dosimetry assessments were analyzed in 231 patients undergoing 329 TARE sessions from 09/2009 to 07/2023. Response was assessed using RECIST1.

View Article and Find Full Text PDF

The colon exhibits higher propensity for tumour development than ileum. However, the role of immune microenvironment differences in driving this disparity remains unclear. Here, by comparing paired ileum and colon samples from patients with colorectal cancer (CRC) and healthy donors, we identified ileum-enriched CD160CD8 T cells with previously unrecognized characteristics, including resistance to terminal exhaustion and strong clonal expansion.

View Article and Find Full Text PDF

Discovery of 2-tetrahydroisoquinoline substituted quinazoline derivatives as lysine methyltransferase G9a inhibitors with in vivo antitumor efficacy.

Eur J Med Chem

September 2025

Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China; State Key Laboratory of Innovative Immunotherapy, Central Research Institute,

Overexpression of protein lysine methyltransferase G9a, which catalyzes mono- and di-methylation of histone H3K9 and non-histone proteins, is closely associated with poor prognosis and metastasis of various cancers. Here, we designed and synthesized a series of novel G9a inhibitors bearing 2-tetrahydroisoquinoline substituted quinazoline scaffold. Among them, compound 31 with 2-dioxole fused tetrahydroisoquinoline exhibited the most potent inhibitory effects against G9a with an IC value of 0.

View Article and Find Full Text PDF

IRF7 drives resistance to oncolytic virotherapy by restricting viral replication and suppressing antitumor immunity.

Biochem Biophys Res Commun

September 2025

State Key Laboratory of Medicinal Chemical Biology and College of Life Science, Nankai University, Tianjin, China. Electronic address:

Oncolytic viruses (OVs) represent a promising approach for cancer immunotherapy by inducing direct tumor lysis and stimulating antitumor immunity. However, tumor-intrinsic resistance remains a major barrier to their efficacy. In this study, we established an OV-resistant MC38 colon cancer model (MC38) and identified interferon regulatory factor 7 (IRF7), a key regulator of type I interferon signaling, as significantly upregulated in resistant cells.

View Article and Find Full Text PDF